Epoprostenol (sodium)

Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[1][2][3].

Product Specifications

CAS Number

[61849-14-7]

Product Name Alternative

Prostaglandin I2 (sodium salt) ; Prostacyclin (sodium salt) ; Flolan

UNSPSC

12352005

Hazard Statement

H302, H302+H312+H332, H312, H332

Target

Apoptosis; Endogenous Metabolite

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/epoprostenol-sodium.html

Purity

99.0

Solubility

H2O : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCCCC[C@H](O)/C=C/[C@@H]1[C@H]([C@@]2([H])C[C@H]1O)C/C(O2)=C/CCCC(O[Na])=O

Molecular Formula

C20H31NaO5

Molecular Weight

374.45

Precautions

H302, H302+H312+H332, H312, H332

References & Citations

[1]Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10 (3) :e0120657.|[2]Lambert O, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted[J]. Drug Design, Development and Therapy, 2012: 61-70.|[3]Akagi S, et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension[J]. International journal of cardiology, 2013, 165 (3) : 499-505.